Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | CCR1 | P32246 | 2/20 | 0.54 |
| ▸ | CCR5 | P51681 | 2/20 | 0.54 |
| ▸ | CCR8 | P51685 | 2/20 | 0.54 |
| ▸ | GMNN | O75496 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.54 |
| ▸ | MMP2 | P08253 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | MMP9 | P14780 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.54 |
| ▸ | MMP8 | P22894 | 1/20 | 0.54 |
| ▸ | THPO | P40225 | 1/20 | 0.54 |
| ▸ | MTOR | P42345 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10614487 | 0.82 | LMNA (0.56) | LMNAMAPTKDM4ESMN1; SMN2CCR1 | |
| SCHEMBL7613781 | 0.81 | LMNA (0.54) | LMNAMAPTKDM4ESMN1; SMN2CCR1 | |
| SCHEMBL12962162 | 0.80 | LMNA (0.52) | LMNAMAPTKDM4ESMN1; SMN2CCR1 | |
| SCHEMBL15961575 | 0.80 | LMNA (0.56) | LMNAMAPTKDM4ESMN1; SMN2CCR1 | |
| SCHEMBL1507898 | 0.80 | HTT (0.55) | LMNAMAPTKDM4ESMN1; SMN2CCR1 | |
| SCHEMBL1058988 | 0.80 | LMNA (0.52) | LMNAMAPTKDM4ESMN1; SMN2CCR1 | |
| SCHEMBL170428 | 0.79 | MEN1 (0.68) | LMNAMAPTKDM4ESMN1; SMN2CCR1 | |
| SCHEMBL30614510 | 0.79 | MEN1 (0.68) | LMNAMAPTKDM4ESMN1; SMN2CCR1 | |
| SCHEMBL20562868 | 0.78 | PDE10A (0.54) | LMNAMAPTKDM4ESMN1; SMN2CCR1 | |
| SCHEMBL1688721 | 0.77 | PDE10A (0.52) | LMNAMAPTKDM4ESMN1; SMN2CCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240148744-A1 | SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | ZOETIS LLC | 2024-05-09 | — | — | US | disclosed |
| EP-4291555-A1 | SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | Celgene Corporation (US) | 2023-12-20 | — | — | EP | disclosed |
| CN-116806218-A | Sulfonamide and its use for the treatment of parasitic helminth infections and diseases | 新基公司 | 2023-09-26 | — | — | CN | disclosed |
| WO-2022173727-A1 | SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | CELGENE CORPORATION (US) | 2022-08-18 | — | — | WO | disclosed |
| US-20220081412-A1 | QUINOLINYL-PYRAZINE-CARBOXAMIDE COMPOUNDS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2022-03-17 | — | — | US | disclosed |
| CN-103492028-B | Sulfonaminoquinoline hepcidin antagonists | 维福（国际）股份公司 | 2017-02-08 | — | — | CN | disclosed |
| EP-2675526-B1 | NOVEL SULFONAMINOQUINOLINE HEPCIDIN ANTAGONISTS | VIFOR (INTERNATIONAL) AG (CH) | 2017-02-01 | — | — | EP | disclosed |
| US-9102688-B2 | Sulfonaminoquinoline hepcidin antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2015-08-11 | — | — | US | disclosed |
| US-20140364424-A1 | Novel Sulfonaminoquinoline Hepcidin Antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2014-12-11 | — | — | US | disclosed |
| CN-103492028-A | Novel sulfonaminoquinoline hepcidin antagonists | VIFOR INT AG | 2014-01-01 | — | — | CN | disclosed |
| US-20120214803-A1 | Novel Sulfonaminoquinoline Hepcidin Antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2012-08-23 | — | — | US | disclosed |
| US-5656634-A | N-aryl and N-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme A: cholesterol acyl transferase (ACAT) | PFIZER INC. (US) | 1997-08-12 | — | — | US | disclosed |
| US-5362878-A | Intermediates for making N-aryl and N-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme A: cholesterol acyl transferase (ACAT) | PFIZER INC. (US) | 1994-11-08 | — | — | US | disclosed |
| WO-1991004027-A1 | NEW N-ARYL AND N-HETEROARYLAMIDE AND UREA DERIVATIVES AS INHIBITORS OF ACYL COENZYME A: CHOLESTEROL ACYL TRANSFERASE (ACAT) | PFIZER INC. (US) | 1991-04-04 | — | — | WO | disclosed |
| EP-0418071-A2 | New N-aryl and N-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme A: cholesterol acyl transferase | PFIZER INC. (US) | 1991-03-20 | — | — | EP | disclosed |
| US-4761475-A | 2,4-diaminopyrimidines substituted with heterobicyclomethyl radicals at the 5 position useful as antibacterials | SCHERING-PLOUGH ANIMAL HEALTH CORPORATION | 1988-08-02 | — | — | US | disclosed |
| US-4587342-A | 2,4-diamino-(substituted-benzopyran(quinolyl,isoquinoly)methyl)pyrimidines useful as antibacterials | SCHERING-PLOUGH ANIMAL HEALTH CORPORATION | 1986-05-06 | — | — | US | disclosed |
| EP-0051879-B1 | SUBSTITUTED PYRIMIDINES, THEIR SYNTHESIS AND COMPOSITIONS CONTAINING THEM, THEIR USE IN MEDICINE AND INTERMEDIATES FOR MAKING THEM | THE WELLCOME FOUNDATION LIMITED (GB) | 1986-02-05 | — | — | EP | disclosed |
| EP-0051879-A2 | Substituted pyrimidines, their synthesis and compositions containing them, their use in medicine and intermediates for making them | THE WELLCOME FOUNDATION LIMITED (GB) | 1982-05-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214803-A1 | Novel Sulfonaminoquinoline Hepcidin Antagonists | HAMP, SLC40A1, FTH1 | LMNA 4127/4885MAPT 4801/4885KDM4E 4215/4885 |
| US-20220081412-A1 | QUINOLINYL-PYRAZINE-CARBOXAMIDE COMPOUNDS AND USES THEREOF | HMGB3, HCCS, ACACA | LMNA 1772/4885MAPT 4430/4885KDM4E 2186/4885 |
| US-20240148744-A1 | SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | ARSA, MRPS2, SULT2A1 | LMNA 1006/4885MAPT 441/4885KDM4E 4149/4885 |
| US-20140364424-A1 | Novel Sulfonaminoquinoline Hepcidin Antagonists | HAMP, SLC40A1, FTH1 | LMNA 4127/4885MAPT 4801/4885KDM4E 4215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.